Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cytokine Release Syndrome Management Market Revenue Growth Supported By A CAGR Of 32.34% Through 2030
The market for managing cytokine release syndrome has experienced robust expansion recently. Projections indicate a rise from $23.76 billion in 2025 to $25.31 billion in 2026, reflecting a compound annual growth rate of 6.5%. Factors contributing to this growth during the past period include the increasing adoption of CAR-T therapies, a scarcity of specific CRS treatment alternatives, a prevalent reliance on corticosteroids, the predominant management approach within hospital settings, and the significant risk of mortality associated with the condition.
The market for managing cytokine release syndrome anticipates a robust upswing in the coming years, projected to reach $32.35 billion by 2030 with a compound annual growth rate of 6.3%. This expansion throughout the forecast period is fueled by several key drivers: the increasing prevalence of cell therapies, progress in immunomodulatory treatments, enhanced capabilities for early diagnosis, the establishment of uniform treatment protocols, and a growing trend in oncology towards adopting these advancements. Significant developments shaping this market include a greater adoption of IL-6 inhibitors, the broadening application of CRS management within CAR-T therapy, an intensified emphasis on proactive intervention strategies, the expansion of critical care monitoring for patients, and the ongoing creation of specialized immunomodulatory agents.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
Cytokine Release Syndrome Management Market Growth Drivers: What Factors Are Accelerating Expansion?
The expansion of the market for managing cytokine release syndrome is anticipated to be significantly influenced by the escalating adoption of targeted therapies. These specialized treatments are engineered to inhibit cancer progression by acting on specific molecular pathways crucial for tumor growth, thereby offering a more precise approach than conventional methods, leading to enhanced effectiveness and fewer adverse effects. Effective management of cytokine release syndrome is critical for maximizing the benefits of these targeted therapies, as it involves mitigating severe inflammatory responses, which in turn bolsters the safety and therapeutic outcomes from treatments like CAR-T cell and immune checkpoint inhibition therapies. Evidence supporting this trend emerged in January 2024, when the American Society of Gene and Cell Therapy reported a 10% increase in gene therapies entering Phase III clinical trials during the final quarter of 2023, representing the first such quarterly advancement since the third quarter of 2022, underscoring the growing landscape of targeted treatment options and consequently, the increasing demand for robust cytokine release syndrome management solutions.
Cytokine Release Syndrome Management Market Segmentation: How Is The Market Structured Across Key Categories?
The cytokine release syndrome management market covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies, Corticosteroids, Intravenous Immunoglobulin (IVIG), Targeted Therapy, Supportive Care, Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation (HSCT), Autoimmune Diseases, Infections, Other Indications
3) By Route Of Administration: Intravenous (IV), Subcutaneous (SC), Oral, Intramuscular (IM), Intrathecal, Other Routes Of Administration
4) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Research Institutions, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab, Siltuximab, Infliximab, Rituximab
2) By Corticosteroids: Dexamethasone, Prednisone, Methylprednisolone, Hydrocortisone
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin, Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin, Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin, Polyvalent Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors, Bruton’s Tyrosine Kinase (BTK) Inhibitors
5) By Supportive Care: Antipyretic Medications, Analgesic Medications, Intravenous Fluids And Electrolyte Solutions, Oxygen Therapy, Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange), Antihistamine Medications, Leukapheresis, Experimental Therapies, Nutritional Support
Cytokine Release Syndrome Management Market Trends: What Is Shaping Future Industry Growth?
Key players within the cytokine release syndrome management sector are prioritizing the execution of clinical studies to pioneer novel treatments, encompassing host-directed small molecule medications intended to fine-tune the immune system’s reaction and mitigate the intensity of cytokine storms, all while preserving the body’s defense mechanisms against pathogens or cancerous cells. These host-directed small molecule compounds, characterized by their low molecular weight, work by targeting specific immune signaling pathways within the host to dampen the overproduction of cytokines, thus aiding in the management of cytokine release syndrome by averting an overreactive immune response. Illustrating this approach, CytoAgents Inc., a biotechnology firm headquartered in the United States, reported in April 2025 the successful conclusion of the initial dose escalation segment in its Phase 1b/2a clinical investigation for CTO1681, a small molecule drug designed to prevent and treat CRS in individuals undergoing CAR T-cell therapy. This experimental treatment exhibited a commendable safety record, showing no toxicities that necessitated dose limitation and no adverse impact on the effectiveness of the CAR T-cells. The ongoing trial, employing a sequential six-dose escalation methodology, aims to evaluate the safety, tolerability, and early signs of effectiveness for CTO1681, in addition to determining the appropriate dosage for subsequent phases of research.
Cytokine Release Syndrome Management Market Competitive Landscape And Leading Companies
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.
Access The Complete Cytokine Release Syndrome Management Market Report:
Cytokine Release Syndrome Management Market Regional Analysis And Leading Geography
North Americawas the largest region in the cytokine release syndrome management market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
